Printer Friendly

Neurocrine in-licenses clinical compound valnoctamide stereoisomer for neurological and psychiatric diseases.

Neurocrine Biosciences, Inc. (San Diego, CA) entered into an exclusive worldwide licensing agreement for the development and commercialization of valnoctamide stereoisomers with Yissum Research Development Company of the Hebrew University (Jerusalem, Israel). Valnoctamide and its individual stereoisomers have been shown to be active in a number of preclinical models and have the potential to treat epilepsy, bipolar disease and neuropathic pain. The parent compound is a uniform combination of four valnoctamide stereoisomers that was marketed as an anxiolytic in several European countries.

While from the same chemical class as valproate (e.g. Depakote and Depakene), a leading antiepileptic drug currently approved for use in the treatment of epilepsy, migraine prophylaxis and bipolar disease, in preclinical studies completed to date, this stereoisomer of valnoctamide has not been associated with the safety concerns (i.e., teratogenicity, and hepatotoxicity) of valproate and its related analogues.

The clinical development of one of the stereoisomers of valnoctamide is intended to offer patients suffering from neurological and psychiatric disorders, a safer and potentially more efficacious treatment option. Neurocrine intends to initiate clinical studies after submission of an investigational new drug application in the first half of 2008.

"This stereoisomer of valnoctamide may provide the opportunity to address many of the current unmet medical needs in the area of neurology and psychiatry by offering patients and their physicians a unique new product profile. We look forward to initiating a clinical development program and plan to file our IND in the first half of 2008," said Christopher F. O'Brien M.D., Senior Vice President and Chief Medical Officer.

"Due to its side effects, the use of valproate is restricted in women of child bearing age and in children. The development of valnoctamide stereoisomers may provide more efficacious and safer CNS drugs and a suitable answer for these clinical needs across all patient types," said Meir Bialer, Ph.D., MBA, a David H. Eisenberg Professor of Pharmacy at Hebrew University. Dr. Bialer, together with Dr. Boris Yagen (Hebrew University), have guided the discovery of the chemical and biological properties of valnoctamide and its individual stereoisomers. Dr. Bialer is a leader in the discovery of antiepileptic agents and has authored over 190 publications in the area of pharmacokinetics, antiepileptics and CNS drugs.

According to IMS Health, sales of valproate derived branded and generic products exceeded $1.5 billion in the United States alone for 2006. With indications possible in therapeutic categories ranging from neurology (epilepsy, migraine pain, and neuropathic pain) to psychiatry (bipolar disorder), commercialization of a stereoisomer of valnoctamide provides the opportunity to access markets accounting for more than $15 billion in drug sales (Med Ad News, 2006) and in excess of 50 million patients (Mattson Jack Group, 2007) on a worldwide basis.

Neurocrine Biosciences is a product-based biopharmaceutical company focused on neurological and endocrine diseases and disorders. The product candidates address some of the largest pharmaceutical markets in the world including insomnia, anxiety, depression, endometriosis, irritable bowel syndrome, pain, and diabetes.

Neurocrine Biosciences, Inc.,

+1-858-617-7600

www.neurocrine.com
COPYRIGHT 2007 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:BIOTECH Patent News
Date:Jul 1, 2007
Words:500
Previous Article:Clarient and Health Discovery initiate alliance with licensing agreement for new molecular diagnostic test for prostate cancer.
Next Article:Xenomics announces issuance of a European patent that covers use of transrenal nucleic acid technology for prenatal diagnostics.
Topics:


Related Articles
Cortex Pharma receives notice of allowance of European patent.
Neurocrine and Taisho restructure diabetes agreement.
Pharmacopeia forms drug screening collaboration.
DOV Pharmaceutical reorganizes indiplon license.
Sirna's collaborator publishes breakthrough research on Huntington's Disease.
Pharmacopeia and Neurocrine expand drug discovery and development collaboration.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters